Kiora Stock Valuation

KPRX
 Stock
  

USD 7.16  0.16  2.29%   

Do you wonder what the value of Kiora Pharmaceuticals is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Kiora Pharmaceuticals, is its stock price multiplied by the total number of shares outstanding, calculating Kiora Pharmaceuticals' enterprise value requires a different approach. It uses Kiora Pharmaceuticals' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Kiora Pharmaceuticals secures a last-minute Real Value of $8.5 per share. The latest price of the firm is $7.16. At this time, the firm appears to be undervalued. Our model forecasts the value of Kiora Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of (158.02) %, current valuation of 5.05 M, and Shares Owned by Insiders of 11.82 % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
  
Kiora Pharmaceuticals Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Kiora Pharmaceuticals's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today 7.16
Please note that Kiora Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Kiora Pharmaceuticals is based on 3 months time horizon. Increasing Kiora Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Kiora Pharmaceuticals is useful when determining the fair value of the Kiora stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Kiora Pharmaceuticals. Since Kiora Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kiora Stock. However, Kiora Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
8.50
Real Value
24.32
Upside
Estimating the potential upside or downside of Kiora Pharmaceuticals helps investors to forecast how Kiora stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kiora Pharmaceuticals more accurately as focusing exclusively on Kiora Pharmaceuticals' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
6.238.1910.14
Details
Hype
Prediction
LowEstimated ValueHigh
0.377.3023.12
Details
Naive
Forecast
LowNext ValueHigh
0.146.7722.59
Details
1 Analysts
Consensus
LowTarget PriceHigh
5.0010.0015.00
Details

Kiora Pharmaceuticals Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Kiora Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kiora Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kiora Pharmaceuticals competition to find correlations between indicators driving Kiora Pharmaceuticals's intrinsic value. More Info.
Kiora Pharmaceuticals is currently regarded as number one stock in price to sales category among related companies. It is currently regarded as number one stock in price to book category among related companies fabricating about  0.02  of Price to Book per Price to Sales. The ratio of Price to Sales to Price to Book for Kiora Pharmaceuticals is roughly  42.30 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kiora Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kiora Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kiora Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kiora Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kiora Pharmaceuticals and how it compares across the competition.

About Kiora Pharmaceuticals Valuation

The stock valuation mechanism determines the current worth of Kiora Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Kiora Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Kiora Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Kiora Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Kiora Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kiora Pharmaceuticals. We calculate exposure to Kiora Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kiora Pharmaceuticals's related companies.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Kiora Pharmaceuticals Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Kiora Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio1.04
Enterprise Value To Ebitda-0.52
Please see Correlation Analysis. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for analysis

When running Kiora Pharmaceuticals price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Kiora Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.